Andrew X Zhu

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
  2. pmc Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1557-66. 2013
  3. doi request reprint First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 19:920-8. 2013
  4. pmc Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues
    Andrew X Zhu
    Massachusetts General Hospital, 55 Fruit Street, Cancer Center POB Room 232, Boston, Massachusetts 02114, USA
    Oncologist 17:1504-7. 2012
  5. doi request reprint Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Semin Oncol 39:493-502. 2012
  6. pmc Targeting insulin-like growth factor axis in hepatocellular carcinoma
    Jennifer Wu
    Division of Hematology and Medical Oncology, NYU Cancer Institute, NYU School of Medicine, New York, NY 10016, USA
    J Hematol Oncol 4:30. 2011
  7. doi request reprint Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer J 15:263-8. 2009
  8. pmc Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    BMC Med 7:42. 2009
  9. pmc Current management of gallbladder carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 15:168-81. 2010
  10. doi request reprint Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Expert Opin Investig Drugs 19:663-72. 2010

Detail Information

Publications88

  1. ncbi request reprint Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:208-13. 2006
    ....
  2. pmc Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Clin Cancer Res 19:1557-66. 2013
    ..We conducted a single-arm phase II study of cediranib, a pan-VEGFR tyrosine kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC)...
  3. doi request reprint First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Clin Cancer Res 19:920-8. 2013
    ..This first-in-man clinical trial was conducted to evaluate the safety, pharmacokinetic characteristics, and preliminary efficacy of GC33 in patients with advanced HCC...
  4. pmc Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues
    Andrew X Zhu
    Massachusetts General Hospital, 55 Fruit Street, Cancer Center POB Room 232, Boston, Massachusetts 02114, USA
    Oncologist 17:1504-7. 2012
    ..The uninvolved liver was unremarkable and a trichrome stain showed no fibrosis. Following an uneventful postoperative recovery, she was referred for consideration of adjuvant therapy...
  5. doi request reprint Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Semin Oncol 39:493-502. 2012
    ..This review will attempt to summarize the current status of other molecularly targeted agents or regimens beyond sorafenib under development in advanced HCC and the future perspectives...
  6. pmc Targeting insulin-like growth factor axis in hepatocellular carcinoma
    Jennifer Wu
    Division of Hematology and Medical Oncology, NYU Cancer Institute, NYU School of Medicine, New York, NY 10016, USA
    J Hematol Oncol 4:30. 2011
    ..IGF axis is increasingly recognized as one of the most relevant pathways in HCC and agents targeting this axis can potentially play an important role in the treatment of HCC...
  7. doi request reprint Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Cancer J 15:263-8. 2009
    ..Here, we review the current progress and future directions for the development of sunitinib in advanced HCC...
  8. pmc Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    BMC Med 7:42. 2009
    ..Whether baseline pERK will prove to be a useful predictive biomarker of response and clinical benefits for sorafenib in HCC will need to be validated in future large prospective studies...
  9. pmc Current management of gallbladder carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 15:168-81. 2010
    ..Molecularly targeted agents are under development. In this review, we attempt to discuss the current status and key issues involved in the management of GBC...
  10. doi request reprint Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA
    Expert Opin Investig Drugs 19:663-72. 2010
    ..The successful approval of sorafenib has greatly stimulated the development of other molecular targeted agents in advanced hepatocellular carcinoma (HCC)...
  11. ncbi request reprint Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 24:1898-903. 2006
    ....
  12. ncbi request reprint Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 11:790-800. 2006
    ..This review attempts to concisely summarize the historical perspective and the current status of systemic therapy development in HCC...
  13. pmc Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study
    Andrew X Zhu
    Division of Hematology Oncology, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Oncol 27:3027-35. 2009
    ..To assess the safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma (HCC) and explore biomarkers for sunitinib response...
  14. ncbi request reprint Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer
    Andrew X Zhu
    Massachusetts General Hospital, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 59:285-93. 2007
    ....
  15. doi request reprint Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors
    Andrew X Zhu
    Massachusetts General Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 15:374-81. 2009
    ..A phase I study was conducted to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of gimatecan, a lipophilic camptothecin analogue, administered orally once a week for 3 weeks...
  16. ncbi request reprint Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer 110:581-9. 2007
    ..A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC...
  17. doi request reprint Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Lancet Oncol 11:48-54. 2010
    ....
  18. ncbi request reprint Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma
    Andrew X Zhu
    Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer 112:250-9. 2008
    ..For this review, the author concisely summarized the current status of molecularly targeted agents that are under clinical development in advanced HCC...
  19. doi request reprint Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 17:1247-56. 2010
    ..The successful clinical development of sorafenib in HCC has ushered in the era of molecularly targeted agents in this disease, which is discussed in this educational review...
  20. pmc Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value
    Andrew X Zhu
    Division of Hematology Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Cancer Res 17:918-27. 2011
    ..Here, we studied the early kinetics of adverse events after sunitinib, and explored their association with circulating proteins and clinical outcome in advanced HCC in a single-arm phase II study...
  21. ncbi request reprint Hepatocellular carcinoma: are we making progress?
    Andrew X Zhu
    Massachusetts General Hospital, Dana Farber Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Invest 21:418-28. 2003
    ..A number of other approaches for decreasing risk in these patients as well as in those with alcoholic-related cirrhosis are currently being evaluated...
  22. ncbi request reprint Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer
    Andrew X Zhu
    Massachusetts General Hospital, Division of Hematology Oncology, Harvard Medical School, Boston, MA, USA
    Clin Colorectal Cancer 3:225-34. 2004
    ..V. bolus 5-FU. The present study offers useful themes for undertaking larger prospective pharmacogenetic studies in the future...
  23. ncbi request reprint Adjuvant therapy for pancreatic cancer: an evolving paradigm
    Andrew X Zhu
    Department of Hematology Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 100 Blossom Street, Cox 640, Boston, MA 02114, USA
    Surg Oncol Clin N Am 13:605-20, viii. 2004
    ..This review highlights historic and current perspectives of adjuvant therapy in resected pancreatic cancer...
  24. pmc Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 117:5094-102. 2011
    ..The phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway plays a critical role in the pathogenesis of hepatocellular carcinoma (HCC). We performed a single-arm, phase 1/2 study of everolimus in patients with advanced HCC...
  25. doi request reprint Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
    Oncologist 13:120-5. 2008
    ..In a phase II study that combined bevacizumab with gemcitabine and oxaliplatin in advanced HCC, we examined computed tomography perfusion (CTp) scan parameters as surrogate markers of angiogenesis after bevacizumab administration...
  26. doi request reprint Early development of sunitinib in hepatocellular carcinoma
    Andrew X Zhu
    Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Expert Rev Anticancer Ther 9:143-50. 2009
    ..Sunitinib has shown early evidence of anti-tumor activity in Phase II trials in US, European and Asian patients with locally advanced, unresectable and metastatic HCC. A Phase III trial of sunitinib in HCC is ongoing...
  27. pmc HCC and angiogenesis: possible targets and future directions
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 8:292-301. 2011
    ....
  28. doi request reprint Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Hepatology 53:695-704. 2011
    ..Here we summarize the relevant molecular pathogenesis, recent and ongoing clinical trials with targeted agents, and the key issues in clinical trial design in BTC...
  29. ncbi request reprint A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma
    Andrew X Zhu
    Massachusetts General Hospital Cancer Center and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Oncologist 10:392-8. 2005
    ..Therefore, we performed a phase II study using the combination of epirubicin and thalidomide in patients with unresectable and metastatic HCC...
  30. ncbi request reprint Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 25:4787-92. 2007
    ..We evaluated an oral regimen of capecitabine and erlotinib in patients with advanced pancreatic cancer who had experienced treatment failure with standard first-line therapy with gemcitabine...
  31. ncbi request reprint Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:1892-7. 2006
    ..To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer...
  32. ncbi request reprint Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Dig Dis Sci 53:564-70. 2008
    ....
  33. pmc Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
    PLoS ONE 7:e38231. 2012
    ..To determine the maximum tolerated dose (MTD) and safety, and explore efficacy and biomarkers of vandetanib with cetuximab and irinotecan in second-line metastatic colorectal cancer...
  34. ncbi request reprint Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 60:661-70. 2007
    ....
  35. doi request reprint A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
    Matthew H Kulke
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 68:293-300. 2011
    ..We performed a prospective, phase II study of 2ME2, administered in combination with bevacizumab, in patients with advanced carcinoid tumors...
  36. pmc Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer
    Brian M Wolpin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Oncologist 18:377-8. 2013
    ..We evaluated tolerability and efficacy of tivozanib (an oral VEGF receptor-1, -2, -3 inhibitor) plus everolimus (an oral mammalian target of rapamycin inhibitor)...
  37. ncbi request reprint Combined modality treatment for rectal cancer
    Andrew X Zhu
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Semin Oncol 32:103-12. 2005
    ..Although 5-fluorouracil (5-FU)-based chemotherapy in combination with RT remains the standard adjuvant therapy for rectal cancer, the integration of novel chemotherapeutic agents and biologic modulators is being actively investigated...
  38. ncbi request reprint Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Dana Farber Cancer Institute, Brigham Women s Hospital, Boston, MA 02115, USA
    Clin Colorectal Cancer 6:59-65. 2006
    ..Whether these results apply to other cancer types is unknown but worthy of further study...
  39. ncbi request reprint A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Institute, Boston, Massachusetts, USA
    Dig Dis Sci 51:1033-8. 2006
    ..4 months. We conclude that while the combination of irinotecan and cisplatin may have activity in aggressive neuroendocrine tumor subtypes, this combination is inactive in patients with well-differentiated neuroendocrine tumors...
  40. pmc FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience
    Jason E Faris
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Oncologist 18:543-8. 2013
    ..However, the recurrences following R0 resection in three of five patients and the toxicities observed with the use of this regimen raise important questions about how to best treat patients with LAPC...
  41. doi request reprint Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab
    Richard S Finn
    Department of Medicine, Division of Hematology Oncology, Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, 11 934 Factor Building, Los Angeles, CA 90095, USA
    Expert Rev Anticancer Ther 9:503-9. 2009
    ..Here, we will review the data supporting the targeting of the VEGF axis in HCC and the preclinical and early clinical development of bevacizumab...
  42. doi request reprint Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer
    Nils D Arvold
    Harvard Radiation Oncology Program, Boston, Massachusetts, USA
    Cancer 118:3026-35. 2012
    ..Neoadjuvant chemotherapy before chemoradiation therapy (CRT) may improve outcomes for patients with locally advanced pancreatic cancer, but optimal management remains controversial, and prior reports have limited follow-up...
  43. doi request reprint Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy
    Nils D Arvold
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 83:e337-43. 2012
    ..The role of adjuvant radiotherapy (RT) in these patients has not been characterized...
  44. doi request reprint Targeted therapy for biliary tract cancers
    Jason E Faris
    Harvard Medical School, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 7E, Boston, MA 02114, USA
    J Hepatobiliary Pancreat Sci 19:326-36. 2012
    ..Data from recent phase I and II trials will be discussed, along with a preview of upcoming trials involving targeted therapies...
  45. pmc Phase II study of pemetrexed in patients with advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Dana 1220, Boston, MA, 02115, USA
    Cancer Chemother Pharmacol 66:961-8. 2010
    ..Pemetrexed is a multitargeted antifolate with activity in tumor types not significantly responsive to other antifolates. We evaluated the efficacy of pemetrexed in a phase II study of patients with advanced neuroendocrine tumors...
  46. doi request reprint A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts Harvard Medical School, Boston, Massachusetts
    Cancer 119:3212-8. 2013
    ..A phase 1/2 study was performed to evaluate the safety and efficacy of temozolomide in combination with everolimus in patients who have advanced pancreatic NET...
  47. doi request reprint Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors
    Jennifer A Chan
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Endocr Relat Cancer 19:615-23. 2012
    ..monthly in combination with everolimus 10  mg daily is feasible and associated with preliminary evidence of antitumor activity in patients with advanced neuroendocrine tumors. Further studies evaluating this combination are warranted...
  48. pmc Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab
    Raymond C Wadlow
    Massachusetts General Hospital, Boston, Massachusetts, USA
    Oncologist 17:14. 2012
    ..We performed a single-arm phase II trial of panitumumab in patients with KRAS wild-type metastatic colorectal cancer that had progressed on prior cetuximab...
  49. pmc Biomarkers of response and resistance to antiangiogenic therapy
    Rakesh K Jain
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Nat Rev Clin Oncol 6:327-38. 2009
    ....
  50. pmc Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis
    Bernardo H L Goulart
    Division of Hematology Oncology, Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    J Hematol Oncol 2:13. 2009
    ..However, a subgroup of patients survives more than 1 year. We analyzed the survival outcomes of this subgroup and evaluated clinical and pathological factors that might affect survival durations...
  51. ncbi request reprint Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors
    Matthew H Kulke
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 24:3555-61. 2006
    ..We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoid or pancreatic neuroendocrine tumors...
  52. ncbi request reprint Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
    David P Ryan
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Cancer 107:2482-9. 2006
    ..The effect of gemcitabine on proteasome inhibition by bortezomib in whole blood was also investigated...
  53. pmc Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Nat Med 10:145-7. 2004
    ..These data indicate that VEGF blockade has a direct and rapid antivascular effect in human tumors...
  54. ncbi request reprint Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver
    Andrew X Zhu
    Cancer Center, Massachusetts General Hospital, Boston, USA
    N Engl J Med 354:1828-37. 2006
  55. doi request reprint A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2
    Joseph Paul Eder
    Early Drug Development Center, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 16:3507-16. 2010
    ..Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity...
  56. doi request reprint Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer
    Andrea L Russo
    Harvard Radiation Oncology Program, Boston, MA, USA
    J Gastrointest Cancer 45:34-9. 2014
    ..Mutations in critical cancer genes may contribute to lack of pCR. We retrospectively evaluated our institutional experience to determine potential mutational and clinical predictors of pCR in patients treated with CRT...
  57. doi request reprint Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib
    Adam D Lipworth
    Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Oncology 77:257-71. 2009
    ..The high prevalence of HFS reported by patients treated with these medications underscores the need for greater understanding of the pathogenesis and management of this syndrome...
  58. ncbi request reprint Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations
    Jennifer F Tseng
    Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Pancreatology 5:67-74. 2005
    ..We sought to determine whether patients undergoing postresection or primary medical treatment for pancreatic adenocarcinoma were immunocompetent...
  59. ncbi request reprint Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer
    Andrew X Zhu
    Massachusetts General Hospital, Dana Farber Partners Cancer Care, Harvard Medical School, Boston, MA, USA
    Semin Radiat Oncol 13:454-68. 2003
    ..In this review, we will discuss the mechanism of action and the key clinical studies of each agent as a radiosensitizer...
  60. doi request reprint MDM2 promoter polymorphism and pancreatic cancer risk and prognosis
    Kofi Asomaning
    Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
    Clin Cancer Res 14:4010-5. 2008
    ..We hypothesized that the G allele is also associated with increased risk and worse outcome in pancreatic cancer...
  61. doi request reprint Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells
    Bryan C Fuchs
    Division of Surgical Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Res 68:2391-9. 2008
    ..These data suggest that EMT predicts HCC sensitivity to EGFR-targeted therapies and that ILK is a novel target to overcome HCC resistance to EGFR inhibition...
  62. pmc Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy
    Dushyant V Sahani
    Division of Abdominal Imaging and Intervention, Harvard Medical School and Massachusetts General Hospital, 55 Fruit Street, White 270, Boston, MA 02114, USA
    J Hematol Oncol 6:51. 2013
    ....
  63. doi request reprint Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma
    Sanjeeva P Kalva
    Center for Image Guided Cancer Therapy and Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, GRB 297, 55 Fruit St, Boston, MA 02114, USA
    J Vasc Interv Radiol 24:257-65. 2013
    ..Multiple Cox regression with backward elimination was performed for terms found significant (P ≤ .05) on univariate analysis...
  64. doi request reprint Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST)
    Tao Jiang
    Division of Abdominal Imaging and Intervention, Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    Invest Radiol 47:11-7. 2012
    ....
  65. pmc Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma
    Vikram Deshpande
    Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, Massachusetts 02114, USA
    BMC Cancer 11:60. 2011
    ..The genetics of advanced biliary tract cancers (BTC), which encompass intra- and extra-hepatic cholangiocarcinomas as well as gallbladder carcinomas, are heterogeneous and remain to be fully defined...
  66. doi request reprint Systemic therapy for biliary tract cancers
    Aram F Hezel
    Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 13:415-23. 2008
    ..In this review, we discuss the clinical experience with systemic treatment of BTC, focusing on the rationale for a first-line regimen as well as future directions in the field...
  67. doi request reprint Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma
    Sadhna R Vora
    Department of Medicine, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts 02114, USA
    Oncologist 14:717-25. 2009
    ..The role of serum alpha-fetoprotein (AFP) as a marker for treatment response in patients with hepatocellular carcinoma (HCC) receiving systemic therapy is poorly defined...
  68. doi request reprint Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver
    James M Cleary
    Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA
    Oncologist 14:1095-105. 2009
    ..Finally, we give specific clinical examples of how multidisciplinary teams can best manage patients receiving preoperative chemotherapy for potentially resectable liver metastases...
  69. pmc Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping
    Darrell R Borger
    Division of Hematology Oncology, Massachusetts General Hospital, Boston 02114 2698, USA
    Oncologist 17:72-9. 2012
    ..These findings define a specific metabolic abnormality in this largely incurable type of gastrointestinal cancer and present a potentially new target for therapy...
  70. ncbi request reprint Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors
    Joseph P Eder
    Dana Farber Cancer Institute, Department of Medical Oncology and Brigham and Women s Hospital, Dana Farber Harvard Cancer Center, Harvard Medical School, Shields Warren Building 460, 44 Binney Street, Boston, MA 02115, USA
    Cancer Chemother Pharmacol 58:107-16. 2006
    ..v. infusion was initiated to determine if the duration of maximum FT inhibition could be significantly extended by prolonging the infusion time and increasing the frequency of administration...
  71. ncbi request reprint Targeting the epidermal growth factor receptor in metastatic colorectal cancer
    Kimmie Ng
    Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
    Crit Rev Oncol Hematol 65:8-20. 2008
    ..Novel strategies of targeting the EGFR pathway to improve efficacy, as well as ongoing research in identifying molecular predictors of response to anti-EGFR agents, will also be reviewed...
  72. ncbi request reprint Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study
    Jessica Y Leung
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Liver Transpl 10:1343-54. 2004
    ..Regardless of which criteria are adopted to define eligibility, strict adherence to the criteria is important to achieve acceptable outcomes...
  73. ncbi request reprint Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience
    Dushyant V Sahani
    Department of Abdominal Imaging and Interventional Radiology, Massachusetts General Hospital, 55 Fruit St, White 270, Boston, MA 02114, USA
    Radiology 243:736-43. 2007
    ..To prospectively assess computed tomographic (CT) perfusion for evaluation of tumor vascularity of advanced hepatocellular carcinoma (HCC) and to correlate CT perfusion parameters with tumor grade and serum markers...
  74. pmc Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Ann Surg 241:295-9. 2005
    ..To analyze the effects of a treatment program of intraoperative electron beam radiation therapy (IOERT) and external beam radiation therapy and chemotherapy on the outcome of patients with unresectable or locally advanced pancreatic cancer...
  75. doi request reprint Cholangiocarcinoma: current and novel imaging techniques
    Nisha I Sainani
    Division of Abdominal Imaging and Interventional Radiology, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
    Radiographics 28:1263-87. 2008
    ..Response to novel targeted therapies can also be assessed with newer imaging tools. Hence, knowledge of current and emerging imaging applications is essential for correct diagnosis and appropriate management of these tumors...
  76. pmc A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma
    Olga N Kozyreva
    Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
    Oncologist 16:310-8. 2011
    ..We performed a multicenter retrospective comparative study to assess the impact of age on potential differences in clinical characteristics, treatment patterns, and outcome in HCC patients...
  77. ncbi request reprint Gemcitabine-associated thrombotic microangiopathy
    Benjamin D Humphreys
    Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 100:2664-70. 2004
    ..015%. Indications for gemcitabine are expanding, and comprehensive characterization of this complication is therefore important...
  78. pmc Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma
    Michael R O'Dell
    James P Wilmot Cancer Center, University of Rochester School of Medicine, Rochester, New York 14642, USA
    Cancer Res 72:1557-67. 2012
    ..These findings establish a new genetically and histopathologically faithful model of IHCC and lend experimental support to the hypothesis that IPBN and VMC are precursors to invasive cancers...
  79. ncbi request reprint Cholangiocarcinoma in association with Thorotrast exposure
    Andrew X Zhu
    Division of Hematology Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    J Hepatobiliary Pancreat Surg 11:430-3. 2004
    ..Radiology, treatment, pathologic findings, and relevant literature are discussed...
  80. ncbi request reprint 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2
    Heather Mernitz
    Nutrition and Cancer Biology Laboratory, Jean Mayer United States Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, 711 Washington Street, Boston, MA 02111, USA
    Cancer Lett 244:101-8. 2006
    ..These results suggest that 9cRA supplementation may provide protection against lung carcinogenesis and this effect may be mediated in part by 9cRA induction of RAR-beta, but not inhibition of COX-2 transcription...
  81. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups
    Eric L Krakauer
    Palliative Care Service, Massachusetts General Hospital, USA
    N Engl J Med 352:817-25. 2005
  82. doi request reprint Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation
    Andrew X Zhu
    JAMA 299:1716-8. 2008
  83. ncbi request reprint Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Andrew X Zhu
    Expert Rev Anticancer Ther 8:499-505. 2008
  84. ncbi request reprint Hepatocellular carcinoma: the need for progress
    Melanie B Thomas
    The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2892-9. 2005
  85. ncbi request reprint Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients
    Christopher G Willett
    J Clin Oncol 23:8136-9. 2005
  86. doi request reprint Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  87. ncbi request reprint Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer
    William Kevin Kelly
    Genitourinary Oncology Service, Division of Solid Tumor, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:2098-107. 2003
    ..The purpose is to determine a safe weekly dose of i.v. estramustine phosphate (EMP) to combine with weekly paclitaxel and monthly carboplatin in patients with advanced prostate cancer...
  88. ncbi request reprint Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?
    Andrew X Zhu
    Cancer 97:2948-50. 2003